ライフサイエンスコーパス: pembrolizumab

1 initial dose level (lenvatinib 24 mg/d plus pembrolizumab).

2 recommended phase 2 dose of margetuximab and pembrolizumab).

3 hibitors and ICIs (ipilimumab, nivolumab and pembrolizumab).

4 b) along with anti-PD-1 checkpoint blockade (pembrolizumab).

5 C), the Expert Panel recommends single-agent pembrolizumab.

6 erapy-resistant disease received BL-8040 and pembrolizumab.

7 d patients who received at least one dose of pembrolizumab.

8 n group having received at least one dose of pembrolizumab.

9 eceived at least one dose of trastuzumab and pembrolizumab.

10 re enrolled and 154 had at least one dose of pembrolizumab.

11 ging at baseline and after at least 4 cycles pembrolizumab.

12 -Johnson syndrome were considered related to pembrolizumab.

13 (3%) of 352 patients receiving placebo plus pembrolizumab.

14 sed could receive an additional 17 cycles of pembrolizumab.

15 ostat plus pembrolizumab versus placebo plus pembrolizumab.

16 d in five of the eight patients who received pembrolizumab.

17 e progression on placebo could cross over to pembrolizumab.

18 h malignant mesothelioma receiving high-dose pembrolizumab.

19 ify which patients with LMD can benefit from pembrolizumab.

20 that bevacizumab will potentiate activity of pembrolizumab.

21 ded phase II dose at lenvatinib 20 mg/d plus pembrolizumab.

22 CC, the Expert Panel recommends single-agent pembrolizumab.

23 ere randomly assigned (1:1:1) to intravenous pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks or

24 Patients were treated with pembrolizumab 10 mg/kg intravenously every 2 weeks.

25 Here, we administered high-dose pembrolizumab (10 mg/kg, day 1, every 2 wk) considering

26 37 patients treated with anti-PD-1 antibody pembrolizumab, 13/16 (81.3%) patients who achieve partia

27 Pembrolizumab (190 RFS events) compared with placebo (28

28 Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months.

29 a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2

30 r 20 mug/kg once per day in combination with pembrolizumab (2 mg/kg every 3 weeks or 200 mg every 3 w

31 Pembrolizumab 200 mg and bevacizumab 15 mg/kg were chose

32 e investigator's discretion, and intravenous pembrolizumab 200 mg every 3 weeks for up to 2 years or

33 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 35 cycles o

34 nd integrated web-response system to receive pembrolizumab 200 mg every 3 weeks intravenously or inve

35 I study to evaluate the clinical activity of pembrolizumab 200 mg every 3 weeks, without restriction

36 n 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks.

37 d 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks.

38 ved margetuximab 10 mg/kg intravenously plus pembrolizumab 200 mg intravenously every 3 weeks and six

39 Participants were given pembrolizumab 200 mg intravenously every 3 weeks for up

40 e epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks or plac

41 d phase 2 dose of margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks.

42 e given axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 a

43 igned double-blind 1:1 to switch maintenance pembrolizumab 200 mg intravenously once every 3 weeks ve

44 took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, i

45 Pembrolizumab 200 mg was administered intravenously on d

46 Fixed-dose pembrolizumab (200 mg absolute, day 1, every 3 wk) for t

47 mum tolerated dose (MTD) for lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks).

48 In phase Ib, pembrolizumab (200 mg) and bevacizumab (10 or 15 mg/kg)

49 ponse system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (

50 ndomly assigned (2:1) to receive intravenous pembrolizumab (200 mg) or saline placebo every 3 weeks f

51 876 metastatic melanoma patients initiating pembrolizumab (44.3%), nivolumab/ipilimumab (31.2%), and

52 (95% confidence interval, CI 43.6-56.5) for pembrolizumab, 58.8% (95% CI 50.5-67.3) for nivolumab, a

53 pacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitu

54 essed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1)

55 g doses of axitinib (2-10 mg) plus flat dose pembrolizumab according to the schedule above.

56 included association between biomarkers and pembrolizumab activity.

57 In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and

58 This led to the approval of pembrolizumab adjuvant treatment by the European Medicin

59 Pembrolizumab adverse events in this study were consiste

60 , 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemothe

61 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembr

62 led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab

63 ilimumab plus nivolumab, nivolumab alone, or pembrolizumab alone should be offered to patients with B

64 nce status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5

65 and antitumour activity of margetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in prev

66 b (an IgG1 VEGFR-2 antagonist) combined with pembrolizumab (an IgG4 PD-1 antagonist) in patients with

67 The objective response rate was 23% with pembrolizumab and 10% with placebo.

68 ) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving plac

69 hs (95% CI, 12.9 months to not reached) with pembrolizumab and 18.7 months (95% CI, 11.4 months to no

70 016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standar

71 3-4 adverse events occurred in 59% receiving pembrolizumab and 38% of patients receiving placebo.

72 ulation was 8.4 months (95% CI 6.4-9.4) with pembrolizumab and 6.9 months (5.9-8.0) with standard of

73 ion cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous tr

74 The combination of 200 mg of pembrolizumab and a 15 mg/kg dose of bevacizumab given e

75 of overall survival (median not reached with pembrolizumab and axitinib vs 35.7 months [95% CI 33.3-n

76 XCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemotherapy in metastatic PDAC (NCT02

77 ith NSCLC who were treated with nivolumab or pembrolizumab and had baseline and follow-up (18)F-FDG P

78 rticipants who received at least one dose of pembrolizumab and had tTMB-high status.

79 to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in

80 DA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent o

81 f 2 anti-programmed cell death 1 antibodies (pembrolizumab and nivolumab) for the treatment of patien

82 tic antibodies (Abs) targeting PD-1, such as pembrolizumab and nivolumab, act through blockade of the

83 complete response after at least 6 months of pembrolizumab and then progressed could receive an addit

84 at least one dose of either margetuximab or pembrolizumab) and the objective response rate as assess

85 53 received pegilodecakin plus pembrolizumab, and 58 received pegilodecakin plus nivolu

86 1-5), and a 200 mg flat dose of intravenous pembrolizumab, and 6 mg/kg of trastuzumab, administered

87 ti-angiogenic second line), and nivolumab or pembrolizumab (anti-PD-1 third line).

88 In 2014, we administered pembrolizumab (anti-PD-1) for ~9 months to a 57-year-old

89 nivolumab (anti-PD-1), 2451 per 100 000 for pembrolizumab (anti-PD-1), 5556 per 100 000 for ipilimum

90 ignation to enfortumab vedotin combined with pembrolizumab as a first-line treatment in February 2020

91 carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combinatio

92 eatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable dise

93 erability of ramucirumab in combination with pembrolizumab assessed by the incidence of adverse event

94 We administered pembrolizumab at a dose of 2 mg per kilogram of body wei

95 s melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or plac

96 score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg/kg every 3 week

97 Four patients discontinued pembrolizumab because of immune-related adverse events.

98 patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred du

99 Pembrolizumab blocks interactions of PD-1 with its ligan

100 Pembrolizumab can be safely combined with trastuzumab an

101 (TPS 1% to 49%), the Expert Panel recommends pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel)

102 An additional treatment option is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel)

103 Additional treatment options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carbo

104 % to 49%) PD-L1, the Expert Panel recommends pembrolizumab/carboplatin/pemetrexed.

105 rogression-free survival was 9.7 months with pembrolizumab-chemotherapy and 5.6 months with placebo-c

106 therapy group, including death in <1% in the pembrolizumab-chemotherapy group and 0% in the placebo-c

107 ow-up was 25.9 months (IQR 22.8-29.9) in the pembrolizumab-chemotherapy group and 26.3 months (22.7-2

108 igned to treatment, with 566 patients in the pembrolizumab-chemotherapy group and 281 patients in the

109 -related adverse event rates were 68% in the pembrolizumab-chemotherapy group and 67% in the placebo-

110 Pembrolizumab-chemotherapy showed a significant and clin

111 plet therapy with dabrafenib, trametinib and pembrolizumab conferred numerically longer progression-f

112 First-line pembrolizumab confers meaningful and durable clinical re

113 Pembrolizumab continued to show superiority over ipilimu

114 Whether PD-1 blockade with pembrolizumab could reinvigorate anti-JC virus immune ac

115 Lenvatinib plus pembrolizumab could represent a new potential treatment

116 Lenvatinib plus pembrolizumab demonstrated a manageable safety profile a

117 The combination of AFM13 with pembrolizumab demonstrated an objective response rate of

118 Pembrolizumab demonstrated durable tumor control, a gene

119 Pembrolizumab demonstrated effective antitumor activity;

120 Pembrolizumab demonstrated significant antitumor activit

121 Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival

122 We and others have reported that pembrolizumab does not affect function or phenotype of t

123 Two cohorts were randomly assigned to a pembrolizumab dose by use of a computer-generated random

124 nd a further four cohorts were assigned to a pembrolizumab dose without randomisation.

125 one dose of study treatment, pooled for all pembrolizumab doses.

126 Exploratory combination of data from the two pembrolizumab dosing regimen groups was not protocol-spe

127 PD-L1 positivity appears to be predictive of pembrolizumab efficacy.

128 , PD-1 blockade with the monoclonal antibody pembrolizumab enhances HIV production in combination wit

129 ral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks.

130 re enrolled and randomly assigned to receive pembrolizumab (every 2 weeks, n=279; every 3 weeks, n=27

131 rtion of patients with objective response to pembrolizumab for each tumour type according to the Resp

132 Patient 1 was on pembrolizumab for his squamous cell carcinoma of the ski

133 luated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or meta

134 atment with GX-188E therapeutic vaccine plus pembrolizumab for patients with recurrent or advanced ce

135 With the landmark approvals of pembrolizumab for the treatment of patients whose tumour

136 n clinical practice, including nivolumab and pembrolizumab for treatment of advanced hepatocellular c

137 intravenously every 3 weeks or placebo plus pembrolizumab for up to 2 years.

138 ab group), thrombocytopenia (14 [26%] in the pembrolizumab group and 12 [21%] in the nivolumab group)

139 ommon of which were anaemia (12 [23%] in the pembrolizumab group and 16 [28%] in the nivolumab group)

140 y 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the

141 (66%) of 111 patients (35 [66%] of 53 in the pembrolizumab group and 38 [66%] of 58 in the nivolumab

142 e nivolumab group), fatigue (11 [21%] in the pembrolizumab group and 6 [10%] in the nivolumab group)

143 and hypertriglyceridaemia (three [6%] in the pembrolizumab group and eight [14%] in the nivolumab gro

144 in 113 (18%) of 636 treated patients in the pembrolizumab group and in 252 (41%) of 615 in the chemo

145 in 96 (17%) of 555 patients in the combined pembrolizumab groups and in 50 (20%) of 256 patients in

146 8.4 months (95% CI 6.6-11.3) in the combined pembrolizumab groups versus 3.4 months (2.9-4.2) in the

147 Pembrolizumab had low antitumour activity in the majorit

148 rticipants who received at least one dose of pembrolizumab, had evaluable tTMB data, and were enrolle

149 Pembrolizumab has activity in brain metastases from NSCL

150 Pembrolizumab has been approved for the treatment of rec

151 anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a fir

152 uch as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy

153 l trials, and larotrectinib, entrectinib and pembrolizumab have received FDA approval for the treatme

154 mab vs 4.9 months, 2.9-6.8, for placebo plus pembrolizumab; hazard ratio [HR] 1.00, 95% CI 0.83-1.21;

155 acadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1.13, 0.86-1.49; one-sided p=0.81).

156 Pembrolizumab improved progression-free survival and ove

157 nd a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial.

158 ometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selecte

159 We assessed the safety and activity of pembrolizumab in combination with trastuzumab and chemot

160 Pembrolizumab in combination with weekly cisplatin-based

161 sion, will report further on the activity of pembrolizumab in Hodgkin lymphoma, microsatellite instab

162 Despite the tissue-agnostic approval of pembrolizumab in mismatch repair deficient (MMRD) solid

163 olled in a Phase I/II trial of niraparib and pembrolizumab in ovarian cancer (NCT02657889).

164 to assess the combination of lenvatinib plus pembrolizumab in patients with advanced endometrial carc

165 e results provide further support for use of pembrolizumab in patients with advanced melanoma.

166 We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung cance

167 alidomide and dexamethasone with and without pembrolizumab in patients with previously untreated mult

168 minary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL.

169 ll survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic h

170 malidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory mu

171 ore conducted a multicohort phase 2 study of pembrolizumab in patients with RR cHL after ASCT, hypoth

172 on of a phase Ib/II study of lenvatinib plus pembrolizumab in patients with selected advanced solid t

173 h assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously trea

174 We conducted a single-arm, phase 2 study of pembrolizumab in patients with solid tumor malignancies

175 overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastati

176 in the full planned doses of ramucirumab and pembrolizumab in phase 1b (n=81).

177 elated adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with st

178 Pembrolizumab induced down-regulation of PD-1 expression

179 wledge, this is the first study to show that pembrolizumab interferes with differentiation of human F

180 re randomly assigned (1:1) to receive 200 mg pembrolizumab intravenously every 3 weeks for up to 35 c

181 Patients received 200 mg of pembrolizumab intravenously every 3 weeks until definiti

182 Pembrolizumab is a humanized monoclonal antibody that bl

183 Pembrolizumab is a monoclonal antibody against PD-1 and

184 MSI-H/MMR-D tumors, for which pembrolizumab is a standard therapy, are more common in

185 Pembrolizumab is active in melanoma brain metastases wit

186 Pembrolizumab is active in melanoma, but activity in pat

187 Single-agent pembrolizumab is an option for low positive PD-L1.

188 Single-agent pembrolizumab is an option in select cases of low positi

189 Although pembrolizumab is approved for recurrent/metastatic head

190 Pembrolizumab is approved for the treatment of advanced

191 Pembrolizumab is associated with high response rate, dur

192 Pembrolizumab is safe and feasible and displays promisin

193 Pembrolizumab is the only immunotherapy agent shown to h

194 Switch maintenance pembrolizumab leads to additional objective responses in

195 ound that rapamycin diminished the effect of pembrolizumab-mediated downregulation of FOXP3.

196 berrant genes in a tissue-agnostic approach: pembrolizumab [microsatellite instability and tumor muta

197 those previously reported for lenvatinib and pembrolizumab monotherapies, apart from an increased fre

198 The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line

199 First-line pembrolizumab monotherapy exhibited promising anti-CSCC

200 First-line pembrolizumab monotherapy improves overall and progressi

201 igated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS o

202 useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously tr

203 Pembrolizumab monotherapy showed durable antitumour acti

204 s who could have a robust tumour response to pembrolizumab monotherapy.

205 ut all three patients remained on commercial pembrolizumab more than 24 months later.

206 2018, 108 patients were randomly assigned to pembrolizumab (n = 55) or placebo (n = 53).

207 clinical trial of dabrafenib, trametinib and pembrolizumab ( NCT02130466 ).

208 metastatic melanoma who started therapy with pembrolizumab, nivolumab, or nivolumab/ipilimumab from J

209 t on Aug 28, 2015, stipulated a flat dose of pembrolizumab of 200 mg every 3 weeks in all Merck-spons

210 atients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib,

211 In this study, we investigated the effect of pembrolizumab on in vitro-induced Tregs (iTregs).

212 The impact of pembrolizumab on RFS was similar in subgroups, in partic

213 better after receiving at least 24 months of pembrolizumab or discontinued with complete response aft

214 Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as ola

215 Pembrolizumab or nivolumab are also reasonable options f

216 Pegilodecakin with pembrolizumab or nivolumab could provide a new therapeut

217 Patients received pembrolizumab or nivolumab with pegilodecakin until dise

218 cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be we

219 t the final appraisal report rejected use of pembrolizumab owing to treatment cost.

220 In multivariable analyses, compared with pembrolizumab, patients starting nivolumab (rate ratio 1

221 ing toxicities were reported in phase 1, and pembrolizumab plasma concentrations were consistent with

222 ly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembro

223 1 patients were randomly assigned to receive pembrolizumab plus axitinib (n=432) or sunitinib monothe

224 nue to support the first-line treatment with pembrolizumab plus axitinib as the standard of care of a

225 ollow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior c

226 ypertension (95 [22%] of 429 patients in the pembrolizumab plus axitinib group vs 84 [20%] of 425 pat

227 continued clinical benefit was observed with pembrolizumab plus axitinib over sunitinib in terms of o

228 EYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy i

229 s to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy

230 th improved GHS/QOL scores at week 21 in the pembrolizumab plus chemotherapy group compared with the

231 , 301 patients were randomly assigned to the pembrolizumab plus lenalidomide and dexamethasone group

232 4%) treatment-related deaths occurred in the pembrolizumab plus lenalidomide and dexamethasone group

233 ts were reported in 81 (54%) patients in the pembrolizumab plus lenalidomide and dexamethasone group

234 (nine [6%]) and pyrexia (seven [5%]) in the pembrolizumab plus lenalidomide and dexamethasone group

235 and randomly assigned 1:1 to receive either pembrolizumab plus lenalidomide and dexamethasone or len

236 12, GHS/QOL scores were maintained with both pembrolizumab plus pemetrexed-platinum (least-squares me

237 , GHS/QOL scores were better maintained with pembrolizumab plus pemetrexed-platinum (least-squares me

238 These data further support use of pembrolizumab plus pemetrexed-platinum as first-line the

239 t baseline, 359 (89%) of 402 patients in the pembrolizumab plus pemetrexed-platinum group and 180 (90

240 402 (99%) of 405 patients in the pembrolizumab plus pemetrexed-platinum group and 200 (99

241 Pembrolizumab plus pemetrexed-platinum led to superior o

242 hed (95% CI 10.2 months to not reached) with pembrolizumab plus pemetrexed-platinum, and was 7.0 mont

243 atients were randomly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group

244 vival was 5.6 months (95% CI 3.7-7.5) in the pembrolizumab plus pomalidomide and dexamethasone group

245 3%) treatment-related deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group

246 occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group

247 last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group

248 rallel cohorts and received the flat dose of pembrolizumab plus standard trastuzumab.

249 Pembrolizumab plus trastuzumab was safe and showed activ

250 RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P

251 advanced ACC that is microsatellite stable, pembrolizumab provided clinically meaningful and durable

252 Pembrolizumab provides durable response and long-term ef

253 hout the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexa

254 e hypothesis that in some patients with PML, pembrolizumab reduces JC viral load and increases CD4+ a

255 Pembrolizumab-related adverse events affected 71% of the

256 ith R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modali

257 The lower discontinuation associated with pembrolizumab should be confirmed in further studies.

258 In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resecte

259 Ramucirumab in combination with pembrolizumab showed a manageable safety profile with fa

260 Lenvatinib plus pembrolizumab showed anti-tumour activity in patients wi

261 tion of GX-188E therapeutic DNA vaccine plus pembrolizumab showed antitumour activity against recurre

262 Lenvatinib plus pembrolizumab showed promising antitumor activity in pat

263 Fewer patients treated with pembrolizumab than with standard of care had grade 3 or

264 Four-and-a-half years after initiating pembrolizumab, the patient remained without evidence of

265 evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in pa

266 ith additional CAR T-cell infusions includes pembrolizumab to improve their efficacy.

267 findings suggest a role for the addition of pembrolizumab to standard chemotherapy for the first-lin

268 The addition of pembrolizumab to standard chemotherapy maintained GHS/QO

269 n and extracerebral responses support use of pembrolizumab to treat small, asymptomatic brain metasta

270 Ingenuity pathway analysis revealed that pembrolizumab-treated iTregs showed upregulation of gene

271 However, pembrolizumab-treated iTregs were relatively less suppre

272 itionally, we found that both nontreated and pembrolizumab-treated iTregs were suppressive.

273 Pembrolizumab treatment continued for up to 24 months.

274 The pembrolizumab treatment effect increased with PD-L1 enri

275 nib together with the PD-1-blocking antibody pembrolizumab (triplet; n = 60) or placebo (doublet; n =

276 death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perfor

277 pulation (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI,

278 tion were 20.0 months (95% CI 15.4-24.9) for pembrolizumab versus 12.2 months (10.4-14.2) for chemoth

279 al was significantly longer with maintenance pembrolizumab versus placebo (5.4 months [95% CI, 3.1 to

280 l trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuz

281 r (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected h

282 II or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab.

283 ked pharmacist), and patients were masked to pembrolizumab versus saline placebo administration.

284 aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the tr

285 months, 95% CI 2.9-6.8, for epacadostat plus pembrolizumab vs 4.9 months, 2.9-6.8, for placebo plus p

286 ot reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1.13, 0.

287 The objective response rate to pembrolizumab was 23% (nine patients; 95% CI, 11% to 39%

288 The objective response rate (ORR) to pembrolizumab was 56% (complete response [24%] plus part

289 Pembrolizumab was administered concurrently with and aft

290 treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar

291 In conclusion, pembrolizumab was successfully administered as post-ASCT

292 Pembrolizumab was well tolerated and showed encouraging

293 death protein 1 (PD-1) agents (nivolumab or pembrolizumab) was conducted to assess overall IRAE rate

294 ated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab wi

295 lizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of

296 e pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in t

297 olizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a pl

298 n cohort 2, 22 patients received BL-8040 and pembrolizumab with chemotherapy, with an ORR, DCR and me

299 patients received vorinostat, tamoxifen and pembrolizumab with no excessive toxicity after progressi

300 Eligible patients who discontinued pembrolizumab with stable disease or better after receiv

301 We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of c